Overview of Periactin

Quick Facts

Property	Description
Active ingredient	Cyproheptadine hydrochloride
Form	Tablets, oral solution, syrup
Pharmacological class	First-generation antihistamine, Serotonin antagonist
General purpose	Modulation of hypersensitivity reactions
Origin	Synthetic piperidine derivative

What is Periactin and What is its Composition?

The medication known by its generic name, Cyproheptadine, is a synthetic compound utilized as a prescription-only medication defined by the active ingredient Cyproheptadine hydrochloride. This single-ingredient product is administered orally, and the drug entity is typically supplied as a pharmaceutical preparation in two key dosage forms: tablets and a liquid oral solution or syrup. The availability in multiple formats ensures it is a versatile option for systemic delivery, including its use in pediatric patients who may require the liquid form. The core composition is the active ingredient combined with a pharmaceutical base, reflecting its identity as a piperidine derivative.

Understanding Cyproheptadine's Pharmacological Class

Cyproheptadine is primarily classified within the pharmacological class of a first-generation antihistamine, functioning as an H1 receptor antagonist. This classification establishes its role in blocking the effects of histamine in the body, a characteristic that has been recognized for decades. A critical feature that distinguishes the chemical substance is its potent secondary action as a Serotonin antagonist at 5-HT2 receptors. This dual action broadens the drug’s effects beyond those of conventional H1 blockers, making it a unique agent in its category.

The General Purpose of this Antagonistic Agent

The general purpose of this antiserotonergic agent is to utilize its potent dual antagonism to stabilize the body's response to certain internal chemical substances, such as during a typical allergic manifestation. By performing Histamine H1 receptor blockade and Serotonin antagonism, the pharmaceutical preparation works to interrupt the cascade of events that lead to symptoms associated with the release of these mediators. The systemic effect of Cyproheptadine makes it a versatile tool for modulating hypersensitivity reactions, providing a general therapeutic benefit by controlling the body’s physiological response to irritants or sensitizing factors.

Regulatory References

What side effects are possible with Periactin?

Possible Side Effects and Safety Information

The safety profile of Cyproheptadine is defined by the official classification of documented adverse reactions and specific usage restrictions, as established in government regulatory documents.

Documented Adverse Reactions

The most frequently observed adverse reaction listed in regulatory texts is sedation or drowsiness, an effect often described as most pronounced during the initial period of treatment but which may diminish after the first few days of continuous administration. Other common effects documented under the Nervous System Disorders and Psychiatric Disorders categories include dizziness, confusion, disturbed coordination, and restlessness. Anticholinergic-like effects, such as dry mouth, are also commonly noted.

Serious Adverse Reactions

Official labeling also documents rare but clinically significant adverse reactions across various organ systems. These include potentially severe effects in Blood and Lymphatic System Disorders, such as agranulocytosis and hemolytic anemia, and Hepato-biliary Disorders, including jaundice and hepatic failure. Serious Cardiovascular effects, such as hypotension and tachycardia, are also listed.

Population-Specific and Regulatory Constraints

Official safety statements define specific populations for whom the use of Cyproheptadine is contraindicated. These restrictions include newborn or premature infants and breast-feeding mothers. Older adults and debilitated patients are also contraindicated due to their heightened susceptibility to adverse reactions like sedation and confusion. Furthermore, the medicine is formally restricted in individuals with pre-existing conditions such as narrow-angle glaucoma, stenosing peptic ulcer, or certain types of urinary obstruction.

Overdose and Emergency Response

The official regulatory profile for Cyproheptadine overdose details a wide range of manifestations that primarily affect the central nervous system (CNS). Documented presentations may range from signs of CNS depression, such as confusion, to CNS stimulation, including restlessness, excitation, and hallucinations. Additionally, atropine-like signs, such as dry mouth, flushing, and fixed and dilated pupils, are recognized presentations.

Overdose is classified as life-threatening due to the risk of severe systemic outcomes, including documented respiratory arrest, cardiac arrest, and the potential for death. This risk is noted to be particularly dangerous in infants and young children, who are more susceptible to CNS stimulation.

Immediate action is required when overdose is suspected. Regulatory guidance mandates that emergency medical attention or the Poison Help line must be contacted. Urgent medical help should be sought by calling emergency services (911) if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management procedures described in the official documents include supportive measures such as gastric lavage, followed by activated charcoal. Intravenous Physostigmine salicylate may be considered for patients exhibiting life-threatening CNS signs and symptoms. The treatment procedures must take into account the patient's age and clinical response to treatment.

Therapeutic Uses of Periactin

What Periactin Treats: Main Uses and Benefits

The primary therapeutic benefit of Cyproheptadine is providing symptomatic relief across distinct clinical domains where symptoms that create noticeable physiological strain cause patient distress. The medication is commonly used in conditions presenting with acute episodes and recurrent symptoms, including perennial and seasonal allergic rhinitis, various forms of urticaria (hives), allergic conjunctivitis, and specific mild allergic skin manifestations.

The core intent is generally to ease the burden of symptoms related to inflammatory or irritative states, such as pronounced itching and rhinitis. The medication is also applied across domains where additional symptomatic support is needed for nutritional intake, playing a supportive role in addressing functional loss of appetite (anorexia) and assisting in maintaining weight stability. Furthermore, it is considered relevant in neurological domains for its supportive therapeutic benefit in addressing episodic vascular headaches, such as migraine.

“The therapeutic intent is generally to assist patients in coping more steadily with disruptive symptom clusters that interfere with daily comfort.”

Quick Fact: Support for Symptoms of Heightened Activity

Cyproheptadine provides support that helps ease the overall symptom burden in situations where symptoms of increased neurological or physiological activity become temporarily overwhelming, contributing to improved day-to-day comfort.

Regulatory References

FDA-approved prescribing information via DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Periactin? (Eligibility Rules)

The official eligibility profile for Periactin (cyproheptadine) is strictly defined by regulatory documents, establishing clear limitations on who may and may not use the medicine.

Contraindicated Populations and Conditions

Use of Periactin is absolutely contraindicated and must be avoided in several patient groups and clinical circumstances, including:

Age: Newborn or premature infants, and elderly, debilitated patients.
Physiological State: Nursing mothers (due to risk to the infant).
Comorbidities: Patients with Angle-Closure Glaucoma, Stenosing Peptic Ulcer, Pyloroduodenal Obstruction, Symptomatic Prostatic Hypertrophy, or Bladder Neck Obstruction.
Acute Status/Drug Therapy: Patients experiencing an Acute Asthmatic Attack, or those receiving Monoamine Oxidase (MAO) Inhibitor therapy.

Age-Group Eligibility and Restrictions

Approved Use: The medicine is officially allowed for use in adults and children aged two years and older.
Pediatric Use: Safety and effectiveness have not been established in children below the age of two years.
Older Adults: While contraindicated in debilitated elderly patients, non-debilitated older adults require cautious dose selection due to potential for reduced organ function.

Conditional Use

Use requires specific caution in patients with conditions such as Hypertension, Hyperthyroidism, Cardiovascular Disease, or a history of Bronchial Asthma, as stated in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory information for cyproheptadine hydrochloride establishes specific interaction constraints, primarily defined by pharmacodynamic effects and formal prohibitions. The regulatory profile is built around additive effects with central nervous system depressants and mandated restrictions on certain co-administered medicinal products.

Documented Interaction Restrictions

Interaction Type	Interacting Substance/Class	Official Constraint
Formal Contraindication	Monoamine Oxidase Inhibitors (MAOIs)	Must not be co-administered; MAOIs intensify anticholinergic effects.
Pharmacodynamic Effect	CNS Depressants (e.g., sedatives, tranquilizers)	Additive effects may increase sedation and central nervous system depression.
Substance Interaction	Alcohol	Additive effects are documented, leading to intensified effects related to central nervous system depression.
Pharmacodynamic Effect	Serotonin-Enhancing Antidepressants (e.g., SSRIs)	May interfere with the pharmacological effects of these agents due to anti-serotonin activity.
Population Restriction	Elderly or Debilitated Patients	Use is formally contraindicated due to documented increased susceptibility to adverse effects.

No mandatory timing-based separation requirements are specified in the regulatory documentation, and the profile contains minimal information regarding specific pharmacokinetic interactions involving CYP enzymes or specific drug transporters. The most severe constraint remains the formal prohibition against concurrent use with MAOIs.

Mechanism of Action

Periactin (cyproheptadine) functions as a non-selective antagonist, primarily targeting several G-protein coupled receptors. Its main actions involve competitive antagonism at the Histamine H1 receptor (H1) and the Serotonin 5-hydroxytryptamine receptors (5-HT2A, 5-HT2C). By occupying the H1 receptor, cyproheptadine prevents the binding of endogenous histamine, thereby stabilizing the receptor in an inactive conformation. This action inhibits the downstream Gq protein signaling pathway, which typically mediates the release of intracellular calcium and activation of Protein Kinase C. Simultaneously, its antagonistic activity at 5-HT2A and 5-HT2C receptors blocks serotonergic neurotransmission in both central and peripheral nervous system tissues. The systemic physiological consequence of H1 antagonism includes modulation of capillary permeability and smooth muscle contractility. The combined antagonism of serotonergic and histaminergic signaling contributes to broad modulation of central nervous system function, including pathways regulating appetite control in the hypothalamus.

Dosage and Administration Information

Official Administration Instructions

Periactin, containing the active ingredient Cyproheptadine hydrochloride, is officially approved for oral administration only. It is supplied as 4 mg tablets and as a liquid oral solution or syrup in a strength of 2 mg per 5 mL.

Dosage must be individualized based on the patient’s clinical needs and response to the medicine. Since the anti-allergic effect of a single dose generally lasts only four to six hours, the total daily amount must be taken in divided doses to maintain the necessary therapeutic level.

Population Group	Initial Labeled Dose	Maximum Daily Dose
Adults	4 mg three times a day (TID)	32 mg (or 0.5 mg/kg/day)
Children 7–14 years	4 mg two or three times a day	16 mg
Children 2–6 years	2 mg two or three times a day	12 mg

For adults, the usual maintenance dose ranges from 12 mg to 16 mg daily, administered in divided doses. Older adults should typically begin treatment at the lower end of the usual dosing range to account for the possibility of reduced clearance and increased sensitivity.

When using the oral solution, a calibrated measuring device should be used for accurate dose administration. The labeling does not specify mandatory timing in relation to meals, but adherence to the divided daily schedule is required to achieve continuous symptomatic support.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Periactin

Evidence for Use in Allergic Conditions

Cyproheptadine was studied for use in managing various conditions characterized by fluctuating or episodic manifestations, such as allergic rhinitis, allergic conjunctivitis, and urticaria (hives). Initial regulatory evaluations were supported by Randomized Controlled Trials (RCTs) that focused on measuring changes in acute allergy symptoms. Studies focused on outcomes related to physical discomfort, including measurements of itching and symptoms linked to inflammatory or irritative states in both Adults and Pediatric Populations. Studies reported that findings describe patterns observed in the cohorts treated for allergic manifestations. Current research indicates that studies comparing Cyproheptadine directly against other types of antihistamine medicines are limited, and research provides limited information for long-term outcomes regarding the sustained control of symptoms over many years.

Evidence for Use in Appetite and Nutritional Support

Research has extensively studied Cyproheptadine for its evaluation in individuals experiencing functional loss of appetite and related research contexts. The evidence base includes a large number of Randomized Controlled Trials and comprehensive Systematic Reviews. Studies monitored groups of Children, Adolescents, and underweight Adult Populations, focusing on outcomes related to systemic or functional imbalance. Studies report that findings describe patterns observed in the cohorts, including measured changes in body weight and nutritional intake. However, the results were mixed or varied among the different study groups, and the certainty remains low regarding the general application of this use. Long-term effects regarding the durability of weight maintenance are not fully established.

Evidence Gaps and Areas of Uncertainty

Research highlights what is known and what is still uncertain about the medicine across all areas of study. Key limitations include that sample sizes were modest in many trials, and follow-up durations were limited across the research landscape. For migraine prophylaxis, the research framework is limited by a limited number of high-quality controlled trials, particularly within the adult population. Certainty remains low in areas where comparative evidence is lacking against current standard therapeutic options. Research provides insight into short-term changes, but the results apply only to the specific conditions and populations studied.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Periactin (FAQ)

Q: How long does it typically take for Periactin to start working?

According to official drug information, the initial effects of the medicine can typically be observed within 15 to 60 minutes after it is taken orally. This indicates that the medicine is absorbed relatively quickly into the body.

Q: How long does the effect of Periactin last after taking it?

The official product information indicates that the anti-allergic effect of a single dose generally lasts between four to six hours. This characteristic explains why official regulatory information describes the total daily amount as typically taken in divided doses to help maintain the intended effects.

Q: Can Periactin be used during pregnancy or while breastfeeding?

Official documentation strictly contraindicates the use of this medicine in nursing or breastfeeding mothers due to potential risks to the infant. Information about use during pregnancy is limited, and official documents state that consideration is required, weighing potential benefit against risk.

Q: Does Periactin interact with common over-the-counter pain relievers?

Regulatory documents include general warnings about additive effects when taken with central nervous system (CNS) depressants, which can increase sedation. Regulatory documents recommend awareness of possible increased effects, particularly when combined with over-the-counter products that contain other sedating ingredients.

Q: Does Periactin interact with supplements or herbal remedies?

Official warnings focus on interactions with substances that affect the central nervous system or serotonin levels. For example, the medicine's pharmacological action may interfere with the effectiveness of certain supplements, such as those that aim to enhance serotonin levels.

Q: Do children experience different side effects from Periactin than adults?

Official labeling notes that in young children, antihistamines may occasionally produce effects such as excitement, restlessness, or irritability. These effects are documented as being the opposite of the more common sedative (drowsiness) effects typically seen in adults and older patients.

Q: What is the typical time frame for seeing the full effect of Periactin for its intended use?

Because a single dose is short-acting, the medicine is taken in divided doses daily to sustain its antiallergic effects. While some research notes a time to effect in the range of several weeks for certain non-allergic studied uses, the time to reach the full benefit for allergy relief is not uniformly defined in official documents.

Q: Is it necessary to take Periactin with food?

The official labeling does not specify mandatory timing in relation to meals. Official product information notes that the medicine may be taken with or without food.

Q: Is Periactin the same as other allergy medicines?

No. The medicine is officially classified as a first-generation antihistamine, but pharmacological studies confirm it has a potent secondary action as a Serotonin antagonist. This dual mechanism of action is what distinguishes it from many other conventional H1 receptor blockers.

Q: Why is Periactin sometimes used for purposes besides allergies?

The reason for its broader study is its pharmacological profile. The medicine’s potent secondary action as a Serotonin antagonist, especially at certain brain receptors, extends its effects beyond typical allergy relief. This activity has led to extensive research regarding its use for appetite control and nutritional support.

Q: Can Periactin affect my mood or energy level?

Yes. Official labeling documents effects on the Central Nervous System, including sedation, confusion, restlessness, excitement, nervousness, irritability, and euphoria. These documented effects may influence both mood and general energy levels.

Q: How is Periactin removed from the body?

The medicine is primarily metabolized (broken down) by the liver and eliminated from the body by the kidneys. Official product information indicates that reduced clearance may occur in the presence of renal (kidney) or hepatic (liver) impairment.

Q: Does Periactin contain gluten or common allergens?

Official drug labeling provides a full list of inactive ingredients, known as excipients, for both the tablets and the oral solution. Patients with specific sensitivities to common allergens or substances like gluten must check this full list in the official regulatory documentation.

Q: Does Periactin lose its effectiveness over time?

Official research frameworks have examined the potential for the development of drug tolerance, known as tachyphylaxis, in certain populations studied. Official research overviews indicate that long-term outcomes, including the durability of effect, are not fully established in all areas of study.

Q: Is Periactin a steroid or a stimulant?

No. The medicine is officially classified as a synthetic compound within the pharmacological class of a first-generation antihistamine and a Serotonin antagonist. It is not classified as a steroid or a stimulant.

Q: Can Periactin be used to help with sleep?

The official, recognized uses of this medicine are for the symptomatic relief of allergic conditions. However, significant sedation or drowsiness is a frequently observed adverse reaction documented in official texts.

Q: Are there any studies comparing Periactin to placebo?

Yes. Initial regulatory evaluations for its approved uses were supported by Randomized Controlled Trials (RCTs), which typically compare the drug against a placebo (an inactive substance). Studies in specific populations have continued to compare the medicine to placebo in research settings.

Q: Can Periactin cause dizziness or lightheadedness?

Yes. The official safety profile documents dizziness and a feeling of faintness among the documented adverse reactions related to the Central Nervous System. Patients should be aware of this potential effect.

Q: What are the disposal guidelines for Periactin?

Unused medication, including tablets and liquid, must be disposed of in accordance with local legal and environmental requirements. Official government guidance mandates that care must be taken to avoid environmental release of the product into waterways.

Q: Is Periactin considered habit-forming?

No. According to the official regulatory documents, no habit-forming tendencies or potential for abuse are reported for this medicine.

Q: Does Periactin interact with common medications for anxiety or depression?

Yes. Official documents indicate that the medicine is known to interact with certain classes of medicines used for anxiety and depression, including CNS Depressants (which can increase sedation) and Serotonin-Enhancing Antidepressants (which may interfere with the drug's anti-serotonin activity). MAO Inhibitors are strictly contraindicated.

Q: Does Periactin cause changes in vision?

Yes. The safety profile documents several effects on the Special Senses, including anticholinergic-like effects such as blurred vision and diplopia (double vision). These effects are listed as possible adverse reactions.

Q: Why might a doctor prescribe Periactin?

The medicine is described in official documents as used for its officially recognized indications, which include the symptomatic relief of various allergic conditions such as hives (urticaria) and allergic rhinitis. Prescribing may also relate to its researched effects on appetite and nutritional support.

How should Periactin be stored and disposed of?

Storage Requirements

Periactin (cyproheptadine HCl) tablets must be stored at Controlled Room Temperature, typically maintained between 20 C to 25 C (68 F to 77 F). To maintain stability, the medication should be dispensed in a well-closed container as defined by official standards.

Protection and Handling

It is an official requirement to keep this medicine out of the reach of children and for the product to be dispensed with a child-resistant closure. Certain liquid or syrup formulations must be protected from light and protected from freezing. Always store Periactin tablets and liquid in a location that preserves the designated temperature and avoids environmental extremes.

Disposal

Official disposal guidelines mandate that any unused Periactin or waste material must be disposed of in accordance with local requirements. Government documents also specify that care must be taken to avoid environmental release into waterways, as the bulk substance is classified as potentially toxic to aquatic organisms.

Periactin